The U.S. FDA said that BD (NYSE:BDX) has expanded its Class I voluntary recall to inform customers about the worst-case performance of the BD Alaris Pump Module model 8100 when used with certain ...
BD will pay a $175 million civil penalty to settle charges from the Securities and Exchange Commission that the company misled investors about problems with its Alaris infusion pumps. The SEC issued a ...
FRANKLIN LAKES, N.J., July 18, 2019 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today provided an update on two voluntary recalls ...
BD has expanded a Class I Alaris recall to cover 15 additional pump infusion sets, the company said Friday. The Food and Drug Administration posted the company's notice on Monday. The company added ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results